首页 > 最新文献

Neurodegenerative disease management最新文献

英文 中文
Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson's disease. YKL-40作为帕金森病生物标志物和治疗靶点的早期研究
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0010
Mai M Anwar, Mohamed H Fathi

Aim: To investigate whether the estimation of cerebrospinal fluid (CSF) and brain YKL-40 levels may be used as an efficient biomarker for Parkinson's disease (PD). Methods: Lipopolysaccharides (LPS) was injected into the right substantia nigra pars compacta (SNpc). Rats were divided into: control group, early LPS-induced PD group (14 days), and advanced LPS-induced PD group (28 days). YKL-40 and other related factors were detected in CSF and brain tissue. Results: Increased expression of YKL-40 was observed in brain tissue and CSF of PD-induced rats associated with triggered inflammatory cytokine release. Conclusion: The current study was limited to detecting YKL-40 and other inflammatory factors in brain and CSF. YKL-40 may be considered as an early biomarker and therapeutic target for PD.

目的:探讨脑脊液(CSF)和脑YKL-40水平的测定是否可作为帕金森病(PD)的有效生物标志物。方法:将脂多糖(LPS)注入右侧黑质致密部(SNpc)。将大鼠分为:对照组、早期lps诱导PD组(14 d)和晚期lps诱导PD组(28 d)。脑脊液及脑组织中检测YKL-40等相关因子。结果:pd诱导大鼠脑组织和脑脊液中YKL-40的表达升高,与触发炎性细胞因子释放有关。结论:目前的研究仅限于检测脑和脑脊液中的YKL-40等炎症因子。YKL-40可能被认为是PD的早期生物标志物和治疗靶点。
{"title":"Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson's disease.","authors":"Mai M Anwar,&nbsp;Mohamed H Fathi","doi":"10.2217/nmt-2022-0010","DOIUrl":"https://doi.org/10.2217/nmt-2022-0010","url":null,"abstract":"<p><p><b>Aim:</b> To investigate whether the estimation of cerebrospinal fluid (CSF) and brain YKL-40 levels may be used as an efficient biomarker for Parkinson's disease (PD). <b>Methods:</b> Lipopolysaccharides (LPS) was injected into the right substantia nigra <i>pars compacta</i> (SNpc). Rats were divided into: control group, early LPS-induced PD group (14 days), and advanced LPS-induced PD group (28 days). YKL-40 and other related factors were detected in CSF and brain tissue. <b>Results:</b> Increased expression of YKL-40 was observed in brain tissue and CSF of PD-induced rats associated with triggered inflammatory cytokine release. <b>Conclusion:</b> The current study was limited to detecting YKL-40 and other inflammatory factors in brain and CSF. YKL-40 may be considered as an early biomarker and therapeutic target for PD.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"85-99"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9942185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Interview with Nobutaka Hattori: a life researching Parkinson's disease pathogenesis. 专访服部信孝:研究帕金森病发病机制的一生。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-04-01 DOI: 10.2217/nmt-2023-0010
Nobutaka Hattori
{"title":"Interview with Nobutaka Hattori: a life researching Parkinson's disease pathogenesis.","authors":"Nobutaka Hattori","doi":"10.2217/nmt-2023-0010","DOIUrl":"https://doi.org/10.2217/nmt-2023-0010","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"71-73"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9624822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parkinson's disease research in Morocco: a review. 摩洛哥帕金森病研究综述
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0021
Mohamed Daghi, Abdelhakim Lakhdar, Hicham El Otmani

Aim: To quantify and provide an overview on the scientific productivity made by Moroccan academics in the research on Parkinson's disease (PD) and parkinsonism. Materials & methods: Scientific articles, in either English or French, were gathered from published literature in three recognized databases: PubMed, ScienceDirect and Scopus. Results: We identified 95 published papers from which 39 articles have been extracted after removing inadequate publications and duplications between databases. All articles were published between 2006 and 2021. The selected articles were subdivided into five categories. Conclusion: The Moroccan academia is presently facing a low productivity issues and a lack of research laboratories focusing on PD research. We anticipate that providing more budgetary funds will significantly improve the productivity of PD research.

目的:量化并概述摩洛哥学者在帕金森氏病(PD)和帕金森氏症研究中的科学生产力。材料与方法:科学文章,英文或法文,从PubMed, ScienceDirect和Scopus这三个公认的数据库中已发表的文献中收集。结果:我们确定了95篇已发表的论文,其中39篇论文在删除不充分的出版物和数据库之间的重复后被提取出来。所有文章发表于2006年至2021年之间。入选的文章被细分为五类。结论:摩洛哥学术界目前面临生产力低下和缺乏专注于PD研究的研究实验室的问题。我们预计,提供更多的预算资金将大大提高PD研究的生产力。
{"title":"Parkinson's disease research in Morocco: a review.","authors":"Mohamed Daghi,&nbsp;Abdelhakim Lakhdar,&nbsp;Hicham El Otmani","doi":"10.2217/nmt-2022-0021","DOIUrl":"https://doi.org/10.2217/nmt-2022-0021","url":null,"abstract":"<p><p><b>Aim:</b> To quantify and provide an overview on the scientific productivity made by Moroccan academics in the research on Parkinson's disease (PD) and parkinsonism. <b>Materials & methods:</b> Scientific articles, in either English or French, were gathered from published literature in three recognized databases: PubMed, ScienceDirect and Scopus. <b>Results:</b> We identified 95 published papers from which 39 articles have been extracted after removing inadequate publications and duplications between databases. All articles were published between 2006 and 2021. The selected articles were subdivided into five categories. <b>Conclusion:</b> The Moroccan academia is presently facing a low productivity issues and a lack of research laboratories focusing on PD research. We anticipate that providing more budgetary funds will significantly improve the productivity of PD research.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"129-139"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of auditory cues on gait variability in people with Parkinson's disease and older adults: a systematic review. 听觉提示对帕金森病患者和老年人步态变异性的影响:一项系统综述。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-04-01 DOI: 10.2217/nmt-2021-0050
Elinor C Harrison, Gammon M Earhart

Aim: The goal of this study was to analyze the effects of external rhythmic auditory stimulation (RAS) on gait variability in older adults and people with Parkinson's disease (PD). Methods: Academic databases searched included PubMed, Web of Science, PEDro and Cochrane, from inception to September 2021. Eligible articles scored a minimum of 4 on the PEDro scale. Results: Twenty-three papers were included. People with PD show varied responses in gait variability to RAS during cued walking trials. Healthy older adults tended to increase variability during cued trials. Cue rates below preferred walking cadence tend to increase gait variability. Conclusion: Gait variability is closely associated with fall risk and an important consideration in development of gait rehabilitation techniques.

目的:本研究的目的是分析外部节律性听觉刺激(RAS)对老年人和帕金森病(PD)患者步态变异性的影响。方法:检索PubMed、Web of Science、PEDro和Cochrane等学术数据库,检索时间为成立至2021年9月。符合条件的文章在佩德罗量表上得分至少为4分。结果:共纳入23篇论文。在提示步行试验中,PD患者对RAS的步态变异性表现出不同的反应。在提示试验中,健康老年人倾向于增加变异性。提示率低于首选步行节奏倾向于增加步态变异性。结论:步态变异性与跌倒风险密切相关,是发展步态康复技术的重要考虑因素。
{"title":"The effect of auditory cues on gait variability in people with Parkinson's disease and older adults: a systematic review.","authors":"Elinor C Harrison,&nbsp;Gammon M Earhart","doi":"10.2217/nmt-2021-0050","DOIUrl":"https://doi.org/10.2217/nmt-2021-0050","url":null,"abstract":"<p><p><b>Aim:</b> The goal of this study was to analyze the effects of external rhythmic auditory stimulation (RAS) on gait variability in older adults and people with Parkinson's disease (PD). <b>Methods:</b> Academic databases searched included PubMed, Web of Science, PEDro and Cochrane, from inception to September 2021. Eligible articles scored a minimum of 4 on the PEDro scale. <b>Results:</b> Twenty-three papers were included. People with PD show varied responses in gait variability to RAS during cued walking trials. Healthy older adults tended to increase variability during cued trials. Cue rates below preferred walking cadence tend to increase gait variability. <b>Conclusion:</b> Gait variability is closely associated with fall risk and an important consideration in development of gait rehabilitation techniques.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"113-128"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9925828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes. 阿波啡舌下膜和左旋多巴对OFF发作患者的运动反应。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0038
Stuart H Isaacson, Alyssa Bowling, Ian Zhang, Eric Pappert, Fabrizio Stocchi

Aim: Evaluate timing of motor improvement with carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO) in patients with Parkinson's disease and OFF episodes. Methods: A post hoc pooled analysis from two studies assessed Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) scores and investigator-rated FULL ON. Results: At 15 and 30 min following the prescribed first daily CD/LD dose, mean improvements in MDS-UPDRS-III scores were -6.7 and -16.3, respectively, and FULL ON was achieved by 6.5 and 41.8% of patients. Following an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7 and 81.0% of patients. Conclusion: Concomitant administration of SL-APO with carbidopa/levodopa may be useful for delayed ON.

目的:评价卡比多巴/左旋多巴(CD/LD)和阿波啡舌下膜(SL-APO)对帕金森病和OFF发作患者运动改善的时机。方法:对两项研究进行事后汇总分析,评估运动障碍学会统一帕金森病评定量表第三部分(MDS-UPDRS-III)评分和研究者评定的FULL ON评分。结果:在规定的首次每日CD/LD剂量后15分钟和30分钟,MDS-UPDRS-III评分的平均改善分别为-6.7和-16.3,达到FULL ON的患者分别为6.5%和41.8%。在优化SL-APO剂量后,MDS-UPDRS-III评分的平均改善为-13.9和-22.9,34.7%和81.0%的患者达到了FULL ON。结论:SL-APO与卡比多巴/左旋多巴合用可有效治疗迟发性ON。
{"title":"Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.","authors":"Stuart H Isaacson,&nbsp;Alyssa Bowling,&nbsp;Ian Zhang,&nbsp;Eric Pappert,&nbsp;Fabrizio Stocchi","doi":"10.2217/nmt-2022-0038","DOIUrl":"https://doi.org/10.2217/nmt-2022-0038","url":null,"abstract":"<p><p><b>Aim:</b> Evaluate timing of motor improvement with carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO) in patients with Parkinson's disease and OFF episodes. <b>Methods:</b> A <i>post hoc</i> pooled analysis from two studies assessed Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) scores and investigator-rated FULL ON. <b>Results:</b> At 15 and 30 min following the prescribed first daily CD/LD dose, mean improvements in MDS-UPDRS-III scores were -6.7 and -16.3, respectively, and FULL ON was achieved by 6.5 and 41.8% of patients. Following an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7 and 81.0% of patients. <b>Conclusion:</b> Concomitant administration of SL-APO with carbidopa/levodopa may be useful for delayed ON.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"75-84"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9623349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Updates and advances in multiple sclerosis neurotherapeutics. 多发性硬化症神经疗法的最新进展。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-02-01 Epub Date: 2022-10-31 DOI: 10.2217/nmt-2021-0058
Moein Amin, Carrie M Hersh

The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding pipeline of agents with novel mechanisms, provide more options for patients with MS. While treatment of MS neuroinflammation is well tailored in the existing DMT armamentarium, concerted efforts are currently underway for identifying neuropathological targets and drug discovery for progressive MS. There is also ongoing research to develop agents for remyelination and neuroprotection. Further insights are needed to guide DMT initiation and sequencing as well as to determine the role of autologous stem cell transplantation in relapsing and progressive MS. This review provides a summary of these updates.

多发性硬化症(MS)神经治疗领域正在迅速发展。新的疾病改变疗法(DMT)的疗效和安全性都有所提高,此外,具有新机制的药物管线也在不断扩大,这为多发性硬化症患者提供了更多选择。虽然现有的 DMT 药物已能很好地治疗多发性硬化症的神经炎症,但目前仍在协力确定神经病理学靶点和发现治疗进展性多发性硬化症的药物。目前还在研究开发用于髓鞘再形成和神经保护的药物。还需要进一步的深入了解,以指导DMT的启动和排序,并确定自体干细胞移植在复发性和进展性多发性硬化症中的作用。本综述概述了这些最新进展。
{"title":"Updates and advances in multiple sclerosis neurotherapeutics.","authors":"Moein Amin, Carrie M Hersh","doi":"10.2217/nmt-2021-0058","DOIUrl":"10.2217/nmt-2021-0058","url":null,"abstract":"<p><p>The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding pipeline of agents with novel mechanisms, provide more options for patients with MS. While treatment of MS neuroinflammation is well tailored in the existing DMT armamentarium, concerted efforts are currently underway for identifying neuropathological targets and drug discovery for progressive MS. There is also ongoing research to develop agents for remyelination and neuroprotection. Further insights are needed to guide DMT initiation and sequencing as well as to determine the role of autologous stem cell transplantation in relapsing and progressive MS. This review provides a summary of these updates.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"47-70"},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. 专家意见对COVID-19疫苗和克拉德里滨片在MS:一个简单的语言总结。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0027
Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout

What is this summary about?: People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.

What were the results?: The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets.

What do the results mean?: Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.

这个总结是关于什么的?患有多发性硬化症(简称MS)的人服用克拉德滨片剂可能会担心他们是否能接种COVID-19疫苗。本摘要详细介绍了先前发表的一篇文章的研究结果,其中一个由10名多发性硬化症专家组成的国际委员会制定了建议,以回答有关服用克拉德滨片剂的多发性硬化症患者(包括复发缓解型或活动性继发性进行性疾病)接种COVID-19疫苗的一些重要问题。结果如何?委员会确定了13项建议,38名投票的MS专家中至少有四分之三(75%)同意这些建议。一般来说,他们建议服用克拉德里滨片剂的MS患者应尽快接种COVID-19疫苗,因为该疫苗被认为既安全又有效,疫苗反应不太可能受到克拉德里滨片剂的影响。这些结果意味着什么?总体而言,服用克拉德滨片剂的多发性硬化症患者应接种COVID-19疫苗以保护自己,除非医疗保健提供者有不同建议。
{"title":"Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.","authors":"Peter Rieckmann,&nbsp;Diego Centonze,&nbsp;Gavin Giovannoni,&nbsp;Le H Hua,&nbsp;Celia Oreja-Guevara,&nbsp;Daniel Selchen,&nbsp;Per Soelberg Sørensen,&nbsp;Patrick Vermersch,&nbsp;Heinz Wiendl,&nbsp;Hashem Salloukh,&nbsp;Bassem Yamout","doi":"10.2217/nmt-2022-0027","DOIUrl":"https://doi.org/10.2217/nmt-2022-0027","url":null,"abstract":"<p><strong>What is this summary about?: </strong>People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.</p><p><strong>What were the results?: </strong>The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets.</p><p><strong>What do the results mean?: </strong>Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"5-13"},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies. 在接受natalizumab或其他疗法治疗的多发性硬化症患者中描述“感觉良好的体验”。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0003
John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila

Aim: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). Methods: Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. Results: The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. Conclusion: This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.

目的:接受natalizumab治疗的复发-缓解型多发性硬化症(RRMS)患者有一种“感觉良好的体验”(FGE)。作者使用接受natalizumab或其他疾病改善疗法(other- dmt)治疗的RRMS患者的调查数据来描述FGE。方法:对使用在线患者社交网络MyMSTeam的RRMS患者的问卷数据进行分析。结果:调查包括347例患者(95例natalizumab;252 other-DMT)。natalizumab比其他dmt患者自我报告的FGE更多(62.1 vs 44.8%;P = 0.001),以及其他身体、情感和认知方面的益处。结论:本研究表明,接受natalizumab治疗的患者比接受其他疾病改善疗法治疗的患者更常报告身体、情绪和认知方面的益处,并有助于表征患者报告的与FGE相关的因素。
{"title":"Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.","authors":"John Foley,&nbsp;Regina Berkovich,&nbsp;Mark Gudesblatt,&nbsp;Elizabeth Luce,&nbsp;Beth Schneider,&nbsp;Carl de Moor,&nbsp;Shirley Liao,&nbsp;Lily Lee,&nbsp;Karthik Bodhinathan,&nbsp;Robin Avila","doi":"10.2217/nmt-2022-0003","DOIUrl":"https://doi.org/10.2217/nmt-2022-0003","url":null,"abstract":"<p><p><b>Aim:</b> Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). <b>Methods:</b> Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. <b>Results:</b> The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. <b>Conclusion:</b> This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"23-34"},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10797634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. 用克拉德里滨片治疗多发性硬化症患者,对流感和水痘疫苗的影响的简单语言总结。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0026
Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert

What is this summary about?: This is a summary of an article originally published in the Multiple Sclerosis Journal. Cladribine tablets (MAVENCLAD®) are an oral (taken by mouth) medication, approved for the treatment of people with relapsing forms of multiple sclerosis (MS, with episodes of new or worsening symptoms). They are administered for a maximum of 10 days per year, over a period of 2 years. Cladribine tablets work by temporarily reducing the number of lymphocytes, which are immune cells that help to fight off infections. Because of this, people with MS (also called PwMS) may have concerns about the effect of cladribine tablets on vaccines, as these work via immune cells to build protection against infection.

What happened in the magnify-ms study?: A study called MAGNIFY-MS investigated how long it takes for cladribine tablets to begin to work in people with a type of MS called highly active relapsing MS. During the study, some participants received their usual vaccinations against flu (influenza) and against the chickenpox virus (also called varicella zoster virus) as part of their routine medical care. The MAGNIFY-MS study gave the researchers an opportunity to look at how cladribine tablets affect the way the flu and chickenpox virus vaccines work in the body.

What were the results?: Cladribine tablets do not affect how well the body responds to flu and chickenpox vaccines.

What do the results mean?: PwMS taking cladribine tablets who are vaccinated against chickenpox, flu or both can be protected against these diseases.

这个总结是关于什么的?这是最初发表在《多发性硬化症杂志》上的一篇文章的摘要。Cladribine片剂(MAVENCLAD®)是一种口服(口服)药物,被批准用于治疗复发型多发性硬化症(MS)患者,伴有新症状发作或症状恶化。它们每年最多使用10天,为期2年。克拉宾片剂的作用是暂时减少淋巴细胞的数量,淋巴细胞是帮助抵抗感染的免疫细胞。正因为如此,患有多发性硬化症(也称为PwMS)的人可能会担心克拉德里滨片对疫苗的影响,因为这些疫苗是通过免疫细胞来建立防止感染的保护的。在放大质谱研究中发生了什么?当前位置一项名为“MAGNIFY-MS”的研究调查了克拉德宾片剂对一种名为“高活性复发性多发性硬化症”的多发性硬化症患者需要多长时间才能开始起作用。在研究期间,一些参与者接受了常规的流感(流感)和水痘病毒(也称为水痘带状疱疹病毒)疫苗接种,这是他们日常医疗保健的一部分。MAGNIFY-MS研究为研究人员提供了一个观察克拉德滨片如何影响流感和水痘病毒疫苗在体内的作用的机会。结果如何?克拉宾片剂不会影响人体对流感和水痘疫苗的反应。这些结果意味着什么?服用克拉德滨片剂的妇女接种过水痘、流感或两者的疫苗,可预防这些疾病。
{"title":"A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.","authors":"Klaus Schmierer,&nbsp;Heinz Wiendl,&nbsp;Celia Oreja-Guevara,&nbsp;Diego Centonze,&nbsp;Anita Chudecka,&nbsp;Sanjeev Roy,&nbsp;Ursula Boschert","doi":"10.2217/nmt-2022-0026","DOIUrl":"https://doi.org/10.2217/nmt-2022-0026","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a summary of an article originally published in the <i>Multiple Sclerosis Journal</i>. Cladribine tablets (MAVENCLAD<sup>®</sup>) are an oral (taken by mouth) medication, approved for the treatment of people with relapsing forms of multiple sclerosis (MS, with episodes of new or worsening symptoms). They are administered for a maximum of 10 days per year, over a period of 2 years. Cladribine tablets work by temporarily reducing the number of lymphocytes, which are immune cells that help to fight off infections. Because of this, people with MS (also called PwMS) may have concerns about the effect of cladribine tablets on vaccines, as these work via immune cells to build protection against infection.</p><p><strong>What happened in the magnify-ms study?: </strong>A study called MAGNIFY-MS investigated how long it takes for cladribine tablets to begin to work in people with a type of MS called highly active relapsing MS. During the study, some participants received their usual vaccinations against flu (influenza) and against the chickenpox virus (also called varicella zoster virus) as part of their routine medical care. The MAGNIFY-MS study gave the researchers an opportunity to look at how cladribine tablets affect the way the flu and chickenpox virus vaccines work in the body.</p><p><strong>What were the results?: </strong>Cladribine tablets do not affect how well the body responds to flu and chickenpox vaccines.</p><p><strong>What do the results mean?: </strong>PwMS taking cladribine tablets who are vaccinated against chickenpox, flu or both can be protected against these diseases.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"15-21"},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9361631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Welcome to Volume 13 of Neurodegenerative Disease Management. 欢迎阅读《神经退行性疾病管理》第 13 卷。
IF 2.6 Q3 CLINICAL NEUROLOGY Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0042
Emily Powell
{"title":"Welcome to Volume 13 of <i>Neurodegenerative Disease Management</i>.","authors":"Emily Powell","doi":"10.2217/nmt-2022-0042","DOIUrl":"10.2217/nmt-2022-0042","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9143453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurodegenerative disease management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1